ozoralizumab

Home
Ligands
ozoralizumab

GtoPdb Ligand ID: 9638

Synonyms: ATN-103 | PF-5230896

Comment: Ozoralizumab is a trivalent albumin-binding nanobody that binds to and neutralises circulating TNFα. This biologic agent is being investigated for anti-inflammatory potential. The peptide sequence for ozoralizumab submitted in its WHO INN record is identical to SEQ ID NO: 96 (TNF30) in patent US8703131 [1], and identifies the albumin nanobody as ALB8. The patent claims a trivalent construct of TNF30-linker-ALB8-linker-TNF30.

No information available.

No information available.

Mechanism Of Action and Pharmacodynamic Effects
TNFα is pro-inflammatory, and is the underlying cause of many of the clinical symptoms associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. Neutralisation of circulating TNFα is a proven disease-modifying mechanism for chronic autoimmune inflammation, with several anti-TNFα agents already approved for clinical use (for example, infliximab, adalimumab, golimumab, and etanercept).

Mechanism Of Action and Pharmacodynamic Effects

TNFα is pro-inflammatory, and is the underlying cause of many of the clinical symptoms associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. Neutralisation of circulating TNFα is a proven disease-modifying mechanism for chronic autoimmune inflammation, with several anti-TNFα agents already approved for clinical use (for example, infliximab, adalimumab, golimumab, and etanercept).